TARS2

Summary

TARS2 (threonyl-tRNA synthetase 2, mitochondrial, HGNC:30740) is a protein-coding gene on chromosome 1q21.2, encoding Threonine–tRNA ligase, mitochondrial (Q9BW92). Catalyzes the attachment of threonine to tRNA(Thr) in a two-step reaction: threonine is first activated by ATP to form Thr-AMP and then transferred to the acceptor end of tRNA(Thr). It is a selective cancer dependency (DepMap: 73.8% of cell lines).

This gene encodes a member of the class-II aminoacyl-tRNA synthetase family. The encoded protein is a mitochondrial aminoacyl-tRNA synthetase. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 4.

Source: NCBI Gene 80222 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mitochondrial disease (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 17
• Clinical variants (ClinVar): 352 total — 2 pathogenic, 16 likely-pathogenic (top 9% of genes corpus-wide)
• GTEx eGene: eQTL in 39 tissues, sQTL in 15 (q < 0.05)
• Phenotypes (HPO): 16
• Cancer dependency (DepMap): dependent in 73.8% of screened cell lines
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.76 (unconstrained)
• MANE Select transcript: NM_025150

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30740
Approved symbol	TARS2
Name	threonyl-tRNA synthetase 2, mitochondrial
Location	1q21.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ12528
Ensembl gene	ENSG00000143374
Ensembl biotype	protein_coding
OMIM	612805
Entrez	80222

Gene structure

Transcript identifiers

Ensembl transcripts: 57 — 28 protein_coding, 21 nonsense_mediated_decay, 5 retained_intron, 3 protein_coding_CDS_not_defined

MANE Select: ENST00000369064

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 4, TSL 3: 2, TSL 5: 5

ENST00000369064, ENST00000369051, ENST00000369053, ENST00000369054, ENST00000460794, ENST00000462578, ENST00000463555, ENST00000466989, ENST00000467982, ENST00000479372, ENST00000480070, ENST00000483046, ENST00000606933, ENST00000895420, ENST00000895421, ENST00000895422, ENST00000895423, ENST00000895424, ENST00000895425, ENST00000895426, ENST00000895427, ENST00000895428, ENST00000923165, ENST00000923166, ENST00000923167, ENST00000923168, ENST00000923169, ENST00000923170, ENST00000923171, ENST00000923172, ENST00000923173, ENST00000948114, ENST00000984830, ENST00000984831, ENST00000984832, ENST00000984833, ENST00000984834, ENST00000984835, ENST00001020868, ENST00001020870, ENST00001020872, ENST00001020874, ENST00001020875, ENST00001020876, ENST00001075501, ENST00001075502, ENST00001075503, ENST00001075504, ENST00001075505, ENST00001075506, ENST00001075507, ENST00001103294, ENST00001103295, ENST00001103296, ENST00001126752, ENST00001126753, ENST00001142906

RefSeq mRNA: 3 — MANE Select: NM_025150 NM_001271895, NM_001271896, NM_025150

CCDS: CCDS60251, CCDS60252, CCDS952

Canonical transcript exons

ENST00000369064 — 18 exons

Exon	Start	End
ENSE00000959658	150490601	150490725
ENSE00001448725	150506916	150507602
ENSE00002228064	150487419	150487516
ENSE00003458298	150496482	150496628
ENSE00003482095	150491394	150491511
ENSE00003604445	150496810	150496908
ENSE00003667634	150491598	150491662
ENSE00003694893	150497530	150497747
ENSE00003695801	150492411	150492489
ENSE00003696240	150505591	150505705
ENSE00003696402	150504906	150504978
ENSE00003696948	150499216	150499293
ENSE00003698259	150498502	150498664
ENSE00003700057	150504335	150504435
ENSE00003700321	150488964	150489087
ENSE00003700676	150498897	150499034
ENSE00003702024	150504632	150504733
ENSE00003723358	150487858	150488054

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 91.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.6934 / max 463.3193, expressed in 1811 samples.

Highest expression (Bgee): gastrocnemius, apex of heart, muscle of leg, hindlimb stylopod muscle, cerebellar vermis.

Genetic regulation across tissues (GTEx eQTL / sQTL)

TARS2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 39 tissues and its splicing (sQTL) in 15 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 54 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Muscle Skeletal	eqtl	1.8e-23	-0.19	1:150348590:T:G
Cells Cultured fibroblasts	eqtl	2.0e-20	+0.66	1:150496780:G:T
Artery Tibial	eqtl	1.9e-15	+0.79	1:150359534:C:T
Nerve Tibial	eqtl	3.9e-15	+0.86	1:150298822:G:A
Skin Sun Exposed Lower leg	eqtl	2.0e-13	-0.20	1:150521449:C:G
Adipose Subcutaneous	eqtl	3.1e-13	+0.24	1:150322682:T:G
Esophagus Mucosa	eqtl	3.8e-13	+0.92	1:150494737:C:CA
Thyroid	eqtl	2.7e-11	+0.68	1:150285405:G:A
Esophagus Gastroesophageal Junction	eqtl	5.0e-11	+0.92	1:150494737:C:CA
Brain Cerebellar Hemisphere	eqtl	9.3e-10	+1.29	1:150274698:C:T
Skin Not Sun Exposed Suprapubic	eqtl	1.3e-09	-0.20	1:150521449:C:G
Adipose Visceral Omentum	eqtl	1.0e-08	-0.16	1:150521449:C:G
Breast Mammary Tissue	eqtl	1.2e-08	-0.22	1:150521449:C:G
Artery Aorta	eqtl	1.2e-08	+0.81	1:150293419:A:C
Esophagus Muscularis	eqtl	4.2e-08	+0.73	1:150517894:C:T
Brain Cerebellar Hemisphere	sqtl	8.6e-08	+1.48	1:150416469:A:T
Brain Frontal Cortex BA9	eqtl	1.3e-06	+0.32	1:150276941:G:GA
Heart Left Ventricle	eqtl	1.6e-06	-0.13	1:150432822:T:C
Brain Cerebellum	eqtl	1.9e-06	+1.30	1:150274698:C:T
Heart Atrial Appendage	eqtl	3.0e-06	+0.13	1:150283177:T:C

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
5106	24.6934	1811

Top tissues by expression

showing 100 of 281 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	91.25	gold quality
apex of heart	UBERON:0002098	91.18	gold quality
muscle of leg	UBERON:0001383	91.07	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.50	gold quality
cerebellar vermis	UBERON:0004720	90.04	gold quality
triceps brachii	UBERON:0001509	89.60	silver quality
right adrenal gland	UBERON:0001233	89.57	gold quality
muscle organ	UBERON:0001630	89.45	gold quality
heart left ventricle	UBERON:0002084	89.10	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.04	gold quality
cerebellar cortex	UBERON:0002129	88.98	gold quality
cerebellar hemisphere	UBERON:0002245	88.98	gold quality
cardiac ventricle	UBERON:0002082	88.82	gold quality
buccal mucosa cell	CL:0002336	88.80	silver quality
right lobe of liver	UBERON:0001114	88.71	gold quality
right frontal lobe	UBERON:0002810	88.58	gold quality
right adrenal gland cortex	UBERON:0035827	88.52	gold quality
left adrenal gland	UBERON:0001234	88.50	gold quality
left adrenal gland cortex	UBERON:0035825	88.17	gold quality
lower esophagus mucosa	UBERON:0035834	88.13	gold quality
prefrontal cortex	UBERON:0000451	88.01	gold quality
granulocyte	CL:0000094	87.95	gold quality
adrenal cortex	UBERON:0001235	87.91	gold quality
cerebellum	UBERON:0002037	87.91	gold quality
adrenal gland	UBERON:0002369	87.70	gold quality
right atrium auricular region	UBERON:0006631	87.62	gold quality
skin of leg	UBERON:0001511	87.41	gold quality
right ovary	UBERON:0002118	87.29	gold quality
Brodmann (1909) area 9	UBERON:0013540	87.27	gold quality
left ovary	UBERON:0002119	87.15	gold quality
tibial nerve	UBERON:0001323	87.10	gold quality
anterior cingulate cortex	UBERON:0009835	87.02	gold quality
right uterine tube	UBERON:0001302	87.00	gold quality
cingulate cortex	UBERON:0003027	86.98	gold quality
heart	UBERON:0000948	86.97	gold quality
right lobe of thyroid gland	UBERON:0001119	86.89	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.87	gold quality
cardiac atrium	UBERON:0002081	86.56	gold quality
gluteal muscle	UBERON:0002000	86.41	silver quality
nucleus accumbens	UBERON:0001882	86.40	gold quality
ectocervix	UBERON:0012249	86.34	gold quality
esophagus mucosa	UBERON:0002469	86.29	gold quality
spleen	UBERON:0002106	86.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.12	gold quality
skin of abdomen	UBERON:0001416	86.05	gold quality
body of stomach	UBERON:0001161	86.01	gold quality
skeletal muscle tissue	UBERON:0001134	86.00	gold quality
frontal cortex	UBERON:0001870	85.90	gold quality
adenohypophysis	UBERON:0002196	85.88	gold quality
neocortex	UBERON:0001950	85.78	gold quality
body of uterus	UBERON:0009853	85.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.53	gold quality
mucosa of transverse colon	UBERON:0004991	85.45	gold quality
pituitary gland	UBERON:0000007	85.42	gold quality
esophagus	UBERON:0001043	85.38	gold quality
right testis	UBERON:0004534	85.35	gold quality
lymph node	UBERON:0000029	85.30	gold quality
spinal cord	UBERON:0002240	85.21	gold quality
caudate nucleus	UBERON:0001873	85.18	gold quality
endocervix	UBERON:0000458	85.07	gold quality
stomach	UBERON:0000945	85.07	gold quality
fundus of stomach	UBERON:0001160	85.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.94	gold quality
left lobe of thyroid gland	UBERON:0001120	84.94	gold quality
amygdala	UBERON:0001876	84.86	gold quality
liver	UBERON:0002107	84.81	gold quality
left testis	UBERON:0004533	84.81	gold quality
small intestine Peyer’s patch	UBERON:0003454	84.80	gold quality
islet of Langerhans	UBERON:0000006	84.75	gold quality
body of pancreas	UBERON:0001150	84.74	gold quality
body of tongue	UBERON:0011876	84.72	silver quality
putamen	UBERON:0001874	84.70	gold quality
colonic epithelium	UBERON:0000397	84.67	gold quality
rectum	UBERON:0001052	84.67	gold quality
hypothalamus	UBERON:0001898	84.64	gold quality
bone marrow cell	CL:0002092	84.63	gold quality
adrenal tissue	UBERON:0018303	84.62	gold quality
left uterine tube	UBERON:0001303	84.60	gold quality
zone of skin	UBERON:0000014	84.55	gold quality
thyroid gland	UBERON:0002046	84.55	gold quality
lower esophagus	UBERON:0013473	84.44	gold quality
lower esophagus muscularis layer	UBERON:0035833	84.43	gold quality
vastus lateralis	UBERON:0001379	84.42	silver quality
minor salivary gland	UBERON:0001830	84.41	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	84.41	gold quality
muscle tissue	UBERON:0002385	84.39	gold quality
quadriceps femoris	UBERON:0001377	84.38	silver quality
brain	UBERON:0000955	84.37	gold quality
transverse colon	UBERON:0001157	84.35	gold quality
ovary	UBERON:0000992	84.26	gold quality
forebrain	UBERON:0001890	84.23	gold quality
telencephalon	UBERON:0001893	84.16	gold quality
cerebral cortex	UBERON:0000956	84.08	gold quality
right coronary artery	UBERON:0001625	84.08	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.07	gold quality
stromal cell of endometrium	CL:0002255	84.03	gold quality
pancreas	UBERON:0001264	83.99	gold quality
mucosa of stomach	UBERON:0001199	83.97	gold quality
muscle layer of sigmoid colon	UBERON:0035805	83.94	gold quality
small intestine	UBERON:0002108	83.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.68

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Skeletal muscle	tissue	29.9	medium
Tongue	tissue	29.0
Putamen	tissue	24.5
Cerebral cortex	tissue	24.4	medium
Somatosensory cortex	tissue	24.4
Liver	tissue	23.7	medium
Midbrain	tissue	23.4
Cerebellum	tissue	23.2	medium
Superior colliculi	tissue	22.6
Basal ganglia	tissue	22.4	medium
Septum	tissue	22.3
Occipital cortex	tissue	22.3
Hippocampal formation	tissue	22.0
Hypothalamus	tissue	21.8
Olfactory bulb	tissue	21.7
Prefrontal cortex	tissue	21.6
Thalamus	tissue	21.6
Ventral forebrain	tissue	21.6
Motor cortex	tissue	21.1
Medulla oblongata	tissue	21.1
Retrosplenial cortex	tissue	21.0
Retrosplenial and cingulate cortex	tissue	20.9
Periaqueductal gray	tissue	20.9
Temporal cortex	tissue	20.9
Substantia nigra	tissue	20.7
Insular cortex	tissue	20.7
Frontal cortex	tissue	20.6
Amygdala	tissue	20.5
Entorhinal cortex	tissue	20.5
Caudate putamen	tissue	20.5
Corpus callosum	tissue	20.2
Pons	tissue	20.0
Spinal cord	tissue	19.9
Heart muscle	tissue	19.0	medium
Parathyroid gland	tissue	16.6	medium
Locus coeruleus	tissue	16.6
Postcentral gyrus	tissue	16.1
Choroid plexus	tissue	15.4
Nucleus accumbens	tissue	14.8
Tonsil	tissue	14.4	medium
Lymph node	tissue	13.7	medium
Retina	tissue	13.5
Kidney	tissue	13.3	high
Hippocampus	tissue	13.2	medium
Epididymis	tissue	12.3	medium
Spleen	tissue	11.8	medium
Thymus	tissue	11.8
Adrenal gland	tissue	11.4	medium
Stomach 1	tissue	11.3	medium
Fallopian tube	tissue	11.0	medium
Skin 1	tissue	10.8	medium
Esophagus	tissue	10.6	medium
Rectum	tissue	10.6	high
Thyroid gland	tissue	10.5	high
Ovary	tissue	10.3	medium
Appendix	tissue	10.0	medium
Colon	tissue	9.7	medium
Breast	tissue	9.6	medium
Smooth muscle	tissue	9.3	low
Bone marrow	tissue	9.3	medium

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Ventral hippocampus (22.0), Dorsal hippocampus (21.0), Subiculum (20.8), White matter (20.2), Dorsal spinal cord (19.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, QRICH1

miRNA regulators (miRDB)

Targeting TARS2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

19 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-3149	98.77	67.13	1639
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-10395-3P	98.10	66.70	1726
HSA-MIR-3152-5P	96.98	66.88	819

Functional genomics

gnomAD constraint: pLI 1.97e-12, LOEUF 0.76, missense Z 2.91 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000369064 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
1:150,487,451–150,491,448	208 / 228.5	0.91	no
1:150,491,449–150,492,436	30 / 64.5	0.47	no
1:150,492,437–150,507,061	466 / 609.5	0.76	no
DepMap (CRISPR cell-line fitness): dependent in 73.8% of screened cell lines.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): KYSE-180 (-1.712), COR-L311 (-1.586), ACC-MESO-1 (-1.515), NCI-H2004 RT (-1.512), EOL-1 (-1.51), HMC-1-8 (-1.487), EWS502 (-1.456), F-36P (-1.447), T-47D (-1.431), COR-L23 (-1.418), TE-11 (-1.395), EW8 (-1.388), SF-295 (-1.371), GCIY (-1.363), SNU-1196 (-1.36).

Literature-anchored findings (GeneRIF, showing 5)

• TARS2 mutations caused fatal mitochondrial encephalomyopathy in two siblings. (PMID:24827421)
• Identification of a TARS2 splicing variant in several human cell lines, which encodes a hmtThrRS derivative lacking a peptide covering a portion of both the editing and the aminoacylation domains. (PMID:26811336)
• Novel compound heterozygous TARS2 variants in a Chinese family with mitochondrial encephalomyopathy: a case report. (PMID:33153448)
• Mitochondrial Threonyl-tRNA Synthetase TARS2 Is Required for Threonine-Sensitive mTORC1 Activation. (PMID:33340489)
• Clinical, neuroradiological, and molecular characterization of mitochondrial threonyl-tRNA-synthetase (TARS2)-related disorder. (PMID:37454282)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tars2	ENSMUSG00000028107
rattus_norvegicus	Tars2	ENSRNOG00000057194
drosophila_melanogaster	ThrRS	FBGN0027081
caenorhabditis_elegans		WBGENE00004189
caenorhabditis_elegans		WBGENE00006617

Paralogs (4): TARS1 (ENSG00000113407), MRPL39 (ENSG00000154719), PARS2 (ENSG00000162396), TARS3 (ENSG00000185418)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1919057) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.

Mouse phenotype (MP)	Records
preweaning lethality, complete penetrance	1
embryonic lethality prior to organogenesis	1
embryonic lethality prior to tooth bud stage	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	Q3ZBV8	94.5%	Diamond
Xenopus tropicalis	Q0V9S0	81.5%	Diamond
Saccharomyces cerevisiae S288C	P04801	62.9%	Diamond
Schizosaccharomyces pombe 972h-	P87144	62.2%	Diamond
Dictyostelium discoideum	Q54J66	60.0%	Diamond
Arabidopsis thaliana	O04630	57.1%	Diamond
Enterocytozoon bieneusi H348	B7XIA1	54.0%	Diamond
Encephalitozoon cuniculi GB-M1	Q8SRH2	54.0%	Diamond
Aeropyrum pernix K1	Q9YFY3	48.9%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ADAMTSL4-AS2	ncRNA	100289061
MIR4257	ncRNA	100422997
MIR6878	ncRNA	102465529
ECM1	protein-coding	1893
ADAMTSL4	protein-coding	54507
FALEC	ncRNA	100874054
RPRD2	protein-coding	23248
PRPF3	protein-coding	9129
MRPS21	protein-coding	54460

Protein

Protein identifiers

Threonine–tRNA ligase, mitochondrial — Q9BW92 (reviewed: Q9BW92)

Alternative names: Threonyl-tRNA synthetase, Threonyl-tRNA synthetase-like 1

All UniProt accessions (5): B4DQF3, Q9BW92, Q5T5E9, U3KQ50, U3KQG0

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the attachment of threonine to tRNA(Thr) in a two-step reaction: threonine is first activated by ATP to form Thr-AMP and then transferred to the acceptor end of tRNA(Thr). Also edits incorrectly charged tRNA(Thr) via its editing domain.

Subunit / interactions. Homodimer.

Subcellular location. Mitochondrion matrix.

Disease relevance. Combined oxidative phosphorylation deficiency 21 (COXPD21) [MIM:615918] A mitochondrial disorder characterized by a lethal encephalomyopathy. Shortly after birth, affected individuals manifest axial hypotonia, limb hypertonia, psychomotor delay, and increased serum lactate. Additional features include subsarcolemmal lipofuscin-positive deposits in muscle, cerebral spongiosis, and hepatic steatosis. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the class-II aminoacyl-tRNA synthetase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BW92-1	1	yes
Q9BW92-2	2

RefSeq proteins (3): NP_001258824, NP_001258825, NP_079426* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002314	aa-tRNA-synt_IIb	Domain
IPR002320	Thr-tRNA-ligase_IIa	Family
IPR004095	TGS	Domain
IPR004154	Anticodon-bd	Domain
IPR006195	aa-tRNA-synth_II	Domain
IPR012675	Beta-grasp_dom_sf	Homologous_superfamily
IPR012676	TGS-like	Homologous_superfamily
IPR012947	tRNA_SAD	Domain
IPR018163	Thr/Ala-tRNA-synth_IIc_edit	Homologous_superfamily
IPR033728	ThrRS_core	Domain
IPR036621	Anticodon-bd_dom_sf	Homologous_superfamily
IPR045864	aa-tRNA-synth_II/BPL/LPL	Homologous_superfamily
IPR047246	ThrRS_anticodon	Domain

Pfam: PF00587, PF02824, PF03129, PF07973

Catalyzed reactions (Rhea)

• tRNA(Thr) + L-threonine + ATP = L-threonyl-tRNA(Thr) + AMP + diphosphate + H(+) (RHEA:24624)

UniProt features (8 total): sequence conflict 2, transit peptide 1, chain 1, domain 1, modified residue 1, splice variant 1, sequence variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BW92-F1	91.19	0.83

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Ligase, Predicted intracellular proteins, Disease related genes, Potential drug targets, Human disease related genes, Congenital disorders of metabolism

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; nucleoplasm

Antibody reliability (HPA): IH approved · IF uncertain

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Phosphoserine	52

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

4 pathways:

ID	Pathway	Evidence
R-HSA-392499	Metabolism of proteins	—
R-HSA-379726	Mitochondrial tRNA aminoacylation	electronic
R-HSA-72766	Translation	—
R-HSA-379724	tRNA Aminoacylation	—

MSigDB gene sets: 229 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_AMINO_ACID_ACTIVATION, GOBP_TRNA_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_MITOCHONDRIAL_TRANSLATION, GOBP_TRANSLATION, MARTIN_VIRAL_GPCR_SIGNALING_UP, GOBP_MITOCHONDRIAL_RNA_METABOLIC_PROCESS, KEGG_AMINOACYL_TRNA_BIOSYNTHESIS, KIM_GASTRIC_CANCER_CHEMOSENSITIVITY, GOBP_REGULATION_OF_TRANSLATIONAL_FIDELITY, REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION, chr1q21, GOCC_MITOCHONDRIAL_MATRIX

GO Biological Process (6): threonyl-tRNA aminoacylation (GO:0006435), mitochondrial threonyl-tRNA aminoacylation (GO:0070159), translation (GO:0006412), tRNA aminoacylation for protein translation (GO:0006418), tRNA aminoacylation (GO:0043039), aminoacyl-tRNA metabolism involved in translational fidelity (GO:0106074)

GO Molecular Function (8): aminoacyl-tRNA deacylase activity (GO:0002161), threonine-tRNA ligase activity (GO:0004829), ATP binding (GO:0005524), protein homodimerization activity (GO:0042803), nucleotide binding (GO:0000166), aminoacyl-tRNA ligase activity (GO:0004812), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), cytoplasm (GO:0005737)

Reactome top-level categories

3 top-level categories:

Category	Pathways
tRNA Aminoacylation	1
Translation	1
Metabolism of proteins	1

GO top-level categories

36 GO namespaces:

Category	Terms
mitochondrion	2
tRNA metabolic process	2
catalytic activity, acting on a tRNA	2
tRNA aminoacylation for protein translation	1
threonyl-tRNA aminoacylation	1
tRNA aminoacylation for mitochondrial protein translation	1
peptidyltransferase activity	1
translational initiation	1
translational elongation	1
translational termination	1
macromolecule biosynthetic process	1
protein metabolic process	1
protein biosynthetic process	1
translation	1
tRNA aminoacylation	1
amino acid activation	1
regulation of translational fidelity	1
carboxylic ester hydrolase activity	1
aminoacyl-tRNA metabolism involved in translational fidelity	1
deacylase activity	1
aminoacyl-tRNA ligase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
identical protein binding	1
protein dimerization activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
ligase activity, forming carbon-oxygen bonds	1
binding	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular organelle lumen	1
intracellular anatomical structure	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 4 of 17 annotations. The rest are phylogenetic / computational / electronic (IEA).

4 experimentally-supported GO terms:

GO term	NS	Evidence
mitochondrion	CC	high-throughput
aminoacyl-tRNA deacylase activity	MF	direct assay
protein homodimerization activity	MF	direct assay
threonine-tRNA ligase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,284 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TARS2	LARS2	Q15031	965
TARS2	LARS1	Q9P2J5	951
TARS2	AARS1	P49588	897
TARS2	IARS2	Q9NSE4	882
TARS2	IARS1	P41252	833
TARS2	AARS2	Q5JTZ9	829
TARS2	PARS2	Q7L3T8	816
TARS2	YARS1	P54577	814
TARS2	HARS1	P12081	808
TARS2	YARS2	Q9Y2Z4	804
TARS2	VARS2	Q5ST30	803
TARS2	VARS1	P26640	797
TARS2	HARS2	P49590	796
TARS2	NARS2	Q96I59	794
TARS2	MARS2	Q96GW9	792

IntAct

Human interaction partners of TARS2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

12 partners by confidence:

Partner	Interaction type	MIscore	Records
ARL6IP1	physical association	0.560	3
ASB6	physical association	0.560	3
DDIT4L	physical association	0.560	3
FKBP7	physical association	0.560	3
MAL2	physical association	0.560	3
PLIN3	physical association	0.560	3
SFT2D1	physical association	0.560	3
SLC17A9	physical association	0.560	3
SYPL1	physical association	0.560	3
TARS3	physical association	0.560	3
TNFRSF10D	physical association	0.560	3
EIF4A2	physical association	0.000	1

BioGRID (184 interactions; top human partners by supporting records): AHSA1 (Affinity Capture-Luminescence; 2 records), CDC37 (Affinity Capture-Luminescence; 2 records), CHORDC1 (Affinity Capture-Luminescence; 2 records), CLPP (Proximity Label-MS; 2 records), CS (Proximity Label-MS; 2 records), CUL3 (Affinity Capture-MS; 2 records), EGFR (Affinity Capture-MS; 2 records), FKBPL (Affinity Capture-Luminescence; 2 records), PARK2 (Affinity Capture-MS; 2 records), AARS2 (Proximity Label-MS), ACE2 (Affinity Capture-MS), ACSM5 (Affinity Capture-MS), ADAM7 (Affinity Capture-MS), AIFM1 (Proximity Label-MS), AK4 (Affinity Capture-MS)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
QRICH1	“up-regulates quantity by expression”	TARS2	“transcriptional regulation”
ATF4	“up-regulates quantity by expression”	TARS2	“transcriptional regulation”

Disease & clinical

Genetic variants

Variant evidence for TARS2: 352 ClinVar records (18 pathogenic / likely pathogenic); 17 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

352 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	16
Uncertain significance	135
Likely benign	111
Benign	50

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 18 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
1174007	NM_025150.5(TARS2):c.1274A>G (p.Glu425Gly)	Likely pathogenic	criteria provided, single submitter	3
143049	NM_025150.5(TARS2):c.845C>T (p.Pro282Leu)	Likely pathogenic	criteria provided, single submitter	2
1174009	NM_025150.5(TARS2):c.1678G>C (p.Asp560His)	Likely pathogenic	criteria provided, single submitter	2
1341959	NM_025150.5(TARS2):c.470C>G (p.Thr157Arg)	Likely pathogenic	criteria provided, single submitter	2
1341960	NM_025150.5(TARS2):c.2143G>A (p.Glu715Lys)	Likely pathogenic	criteria provided, single submitter	2
432091	NM_025150.5(TARS2):c.1756C>T (p.Arg586Ter)	Likely pathogenic	criteria provided, single submitter	1
2663569	NM_025150.5(TARS2):c.191C>G (p.Ser64Ter)	Likely pathogenic	criteria provided, single submitter	1
3892600	NM_025150.5(TARS2):c.996T>G (p.Tyr332Ter)	Likely pathogenic	criteria provided, single submitter	1
4072010	NM_025150.5(TARS2):c.774G>T (p.Ser258=)	Likely pathogenic	criteria provided, single submitter	1
4072011	NM_025150.5(TARS2):c.1099C>T (p.His367Tyr)	Likely pathogenic	criteria provided, single submitter	1
4845769	NM_025150.5(TARS2):c.1037G>A (p.Arg346His)	Likely pathogenic	criteria provided, single submitter	1
3767312	TARS2, 1-BP DUP, NT988	Pathogenic	no assertion criteria provided	1
3767313	R171K	Pathogenic	no assertion criteria provided	1
1992417	NM_025150.5(TARS2):c.464C>T (p.Pro155Leu)	Likely pathogenic	no assertion criteria provided	1
1992419	NM_025150.5(TARS2):c.1318G>A (p.Glu440Lys)	Likely pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore TARS2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 20 predictions of 1,519):

Position(s)	Effect	Δscore	Sites
1:150488924	acceptor_gain	1.0000
1:150488942	acceptor_gain	1.0000
1:150488948	acceptor_gain	1.0000
1:150488955–150488956	acceptor_gain	1.0000	2
1:150488959	acceptor_gain	1.0000
1:150489088–150489089	donor_loss	1.0000	5
1:150491524	donor_gain	1.0000
1:150499035–150499036	donor_loss	1.0000	4
1:150499205	acceptor_gain	1.0000
1:150499213–150499215	acceptor_gain	1.0000	3

AlphaMissense

1,038 missense substitutions predicted likely pathogenic (of 4,613 scored), across 309 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D457	8	0.945	0.986
D560	8	0.929	0.964
D458	8	0.912	0.968
N408	8	0.902	0.989
H585	8	0.884	0.980
F567	8	0.883	0.973
H460	8	0.878	0.943
F454	8	0.867	0.965
F535	8	0.859	0.982
F433	8	0.853	0.966
F462	8	0.846	0.968
H367	8	0.840	0.958
H412	8	0.831	0.943
D432	8	0.826	0.929
D106	8	0.759	0.844
W362	7	0.949	0.983
F416	7	0.938	0.981
W508	7	0.930	0.974
F348	7	0.925	0.981
W610	7	0.887	0.973

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Disease associations

OMIM: gene MIM:612805 | disease phenotypes: MIM:615918

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
combined oxidative phosphorylation defect type 21	Definitive	Autosomal recessive	5

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

2 validity classifications:

Disease	Classification	Inheritance
Leigh syndrome	Limited	AR
mitochondrial disease	Definitive	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (11 panels, 10 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

11 panels:

Panel	Rating
Dystonia, chorea or related movement disorder, childhood onset	green
Early onset or syndromic epilepsy	green
Hypotonic infant	green
Intellectual disability	green
Leukodystrophy, childhood onset	green
Likely inborn error of metabolism	green
Mitochondrial disorders	green
Paediatric disorders	green
Possible mitochondrial disorder, nuclear genes	green
Unexplained death in infancy and sudden unexplained death in childhood	green
Neonatal diabetes	amber

Mondo (1): combined oxidative phosphorylation defect type 21 (MONDO:0014398)

Orphanet (1): Combined oxidative phosphorylation defect type 21 (Orphanet:420733)

HPO phenotypes

16 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000817	Reduced eye contact
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001397	Hepatic steatosis
HP:0002059	Cerebral atrophy
HP:0002079	Hypoplasia of the corpus callosum
HP:0002151	Increased circulating lactate concentration
HP:0002509	Limb hypertonia
HP:0003348	Hyperalaninemia
HP:0003577	Congenital onset
HP:0003593	Infantile onset
HP:0003811	Neonatal death
HP:0008358	Hyperprolinemia
HP:0008936	Axial hypotonia
HP:0011813	Increased cerebral lipofuscin

GWAS associations

17 associations:

Study	Trait	p-value
GCST010700_28	Cortical thickness (MOSTest)	8e-38
GCST007565_182	Morning person	6e-30
GCST007576_401	Chronotype	6e-30
GCST90002400_128	Plateletcrit	3e-24
GCST010696_2	Cortical thickness (min-P)	2e-23
GCST90013405_109	Liver enzyme levels (alanine transaminase)	2e-20
GCST003837_3	Chronotype	6e-17
GCST010002_27	Refractive error	3e-15
GCST90011898_2	Alanine aminotransferase levels	1e-12
GCST010701_57	Cortical surface area (MOSTest)	9e-12
GCST010703_294	Brain morphology (MOSTest)	9e-12
GCST010702_101	Subcortical volume (MOSTest)	4e-9
GCST010697_28	Cortical surface area (min-P)	9e-9
GCST010698_54	Subcortical volume (min-P)	2e-8
GCST010699_28	Brain morphology (min-P)	3e-8
GCST010245_43	LDL cholesterol levels	4e-8
GCST003838_10	Morning vs. evening chronotype	5e-7

EFO canonical traits (from GWAS)

5 canonical traits:

EFO ID	Trait name
EFO:0008328	chronotype measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3351186 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.23	Kd	5.919	nM	CHEMBL5653589
8.23	ED50	5.919	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149549: Binding affinity to human TARS2 incubated for 45 mins by Kinobead based pull down assay	kd	0.0059	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	affects cotreatment, decreases expression	2
Cadmium Chloride	decreases expression	2
bisphenol A	decreases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
gossypol acetic acid	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
aflatoxin B2	increases methylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Coumestrol	increases expression, affects cotreatment	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Phenobarbital	affects expression	1
Potassium Dichromate	decreases expression	1
Theophylline	affects cotreatment, decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3383853	Binding	Inhibition of threonyl tRNA synthetase (unknown origin) assessed as depletion of tRNAs at 50 uM by SToPs assay	Borrelidin B: isolation, biological activity, and implications for nitrile biosynthesis. — *J Nat Prod*

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0QJ	Ubigene HeLa TARS2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 210 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04201509	Not specified	COMPLETED	Validity of Neurocognitive Assessment Methods in Childhood ADHD
NCT04233775	Not specified	UNKNOWN	Altered Cerebral Growth and Development in Infants With Congenital Heart Disease
NCT04313283	Not specified	COMPLETED	Translating Peer-to-Peer Support Into a Clinical Setting

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for TARS2 across ~30M SureChEMBL compounds — explore on Sugi Predict.